Roberts E A, Spielberg S P, Goldbach M, Phillips M J
Department of Paediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.
J Hepatol. 1990 Mar;10(2):235-9. doi: 10.1016/0168-8278(90)90058-y.
Severe hepatotoxicity from phenobarbital occurred in an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis. Skin rash began after 2 weeks of treatment, and signs of hepatocellular failure developed 3 weeks after phenobarbital had been started. Signs of severe liver disease included elevated aminotransferases, conjugated hyperbilirubinemia, significant coagulopathy, hepatosplenomegaly and ascites. Other features of this adverse drug reaction were unremitting fever, leukocytosis with eosinophilia and atypical lymphocytosis, and proteinuria. Sepsis, viral hepatitis, and metabolic liver disease were excluded. The child was on no other medication and had been previously well. In-vitro rechallenge of the patient's lymphocytes with cytochrome P-450 generated metabolites of phenobarbital showed extensive cytotoxicity compared to control. These data support the hypothesis that a defect in drug detoxification was responsible for the child's susceptibility to this drug hepatotoxicity.
一名患有慢性双侧硬膜下血肿和败血症等复杂疾病的男婴出现了苯巴比妥所致的严重肝毒性。治疗2周后出现皮疹,在开始使用苯巴比妥3周后出现肝细胞衰竭迹象。严重肝病的体征包括转氨酶升高、结合胆红素血症、明显的凝血障碍、肝脾肿大和腹水。这种药物不良反应的其他特征包括持续发热、嗜酸性粒细胞增多和非典型淋巴细胞增多的白细胞增多症以及蛋白尿。排除了败血症、病毒性肝炎和代谢性肝病。该患儿未服用其他药物,之前身体健康。与对照组相比,用细胞色素P - 450生成的苯巴比妥代谢产物对患者淋巴细胞进行体外再激发试验显示出广泛的细胞毒性。这些数据支持这样一种假设,即药物解毒缺陷是导致该患儿易患这种药物肝毒性的原因。